Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuneering Corporation filings document the disclosure record of a late-stage clinical oncology company developing Deep Cyclic Inhibitors for cancer. Recent Form 8-K reports cover operating and financial results, R&D spending, capital resources, and clinical updates for atebimetinib (IMM-1-104), including its evaluation with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
Proxy materials describe annual meeting matters for holders of Class A common stock, including director elections, auditor ratification, board governance and voting procedures. The filing record also includes material-event disclosures addressing material agreements, capital-structure matters, shareholder votes, and regulatory and clinical disclosures for the company’s oncology development programs.
Immuneering Corporation (Nasdaq: IMRX) filed a Rule 424(b)(5) prospectus supplement dated June 23, 2025 that updates its existing at-the-market (ATM) offering program.
Key points:
- Public float: Updated to approximately $83.1 million, calculated on 30,016,759 non-affiliate shares at $2.77 on 6/18/25.
- Because float now exceeds $75 million, IMRX is no longer subject to the sales limitation of Form S-3 General Instruction I.B.6, which had capped sales to one-third of public float over any 12-month period.
- ATM activity to-date: 6,155,556 shares sold for gross proceeds of $18.7 million.
- Remaining capacity: Company may now issue up to an additional $31.29 million of Class A common stock through Piper Sandler under the 8/10/22 Equity Distribution Agreement.
- Market context: Last reported share price on 6/20/25 was $2.56, implying potential dilution if new shares are issued near current levels.
Investors should review the “Risk Factors” section referenced in the base ATM prospectus, as the filing states that investing in IMRX shares involves a high degree of risk.
Immuneering Corporation (IMRX) – Form 4 insider transaction: On 06/18/2025, President, CEO, Director and 10% owner Benjamin J. Zeskind bought 21,000 shares of Class A common stock on the open market at a weighted-average price of $2.3878 per share (trades ranged $2.31-$2.44). The filing was signed on 06/20/2025.
Following the purchase, Zeskind directly owns 2,302,852 shares. In addition, an indirect holding of 894,927 shares is held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse serves as sole trustee. The transaction was coded “P” (open-market purchase), indicating an increase in ownership. The form does not reference any Rule 10b5-1 trading plan.
The purchase represents roughly 0.9% of Zeskind’s direct stake and signals continued insider support, but the absolute amount (≈$50 k) is modest relative to his existing 3.2 million-share economic interest.